Cullinan Therapeutics (CGEM) Change in Acquisitions & Divestments (2020 - 2026)

Cullinan Therapeutics' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $52.5 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 67.69% year-over-year to $52.5 million; the TTM figure through Mar 2026 stood at $306.5 million (down 49.19% YoY), while the FY2025 annual figure was $416.6 million, down 28.77% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $52.5 million, up from $42.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $184.0 million in Q4 2024, with the low at $42.0 million in Q4 2025.
• The 5-year median for Change in Acquisitions & Divestments is $104.5 million (2023), against an average of $106.8 million.
• The sharpest annual moves came in 2022 and 2025: Change in Acquisitions & Divestments surged 662.08% in 2022, then plunged 77.17% in 2025.
• Cullinan Therapeutics' Change in Acquisitions & Divestments stood at $132.6 million in 2022, then dropped by 11.4% to $117.5 million in 2023, then jumped by 56.62% to $184.0 million in 2024, then slumped by 77.17% to $42.0 million in 2025, then climbed by 25.12% to $52.5 million in 2026.
• Business Quant data shows CGEM's Change in Acquisitions & Divestments at $52.5 million in Q1 2026, $42.0 million in Q4 2025, and $80.0 million in Q3 2025.